PATENT CLAIM ANALYSIS

Application Number: 15868252
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "018900"]

Abstract:
The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto

Claim (Index 4):
The synthetic peptide of  claim 1 , wherein the analogue is completely inverso modified.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 86.0
- Lexical Diversity: 1.41176
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13397548', '14907445', '11817869', '12296239', '14589680']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.810162260783426
- 35 USC 102 Novelty (BERT): 0.548884902158057
- Combined Prediction Score: 0.7840345249208891
- Mean Citation Score: 356.13662800000014
- Max Citation Score: 422.55023
- Similarity Product: 291.0581801154995

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test